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ORIGINAL ARTICLE
Effects of Achieving Target Measures in
Rheumatoid Arthritis on Functional Status,
Quality of Life, and Resource Utilization:
Analysis of Clinical Practice Data
EVO ALEMAO,1 SEONGJUNG JOO,2 HUGH KAWABATA,2 MAIWENN J. AL,3 PAUL D. ALLISON,4
MAUREEN P. M. H. RUTTEN-VAN M€OLKEN,3 MICHELLE L. FRITS,5 CHRISTINE K. IANNACCONE,5
NANCY A. SHADICK,5 AND MICHAEL E. WEINBLATT5
Objective. To evaluate associations between achieving guideline-recommended targets of disease activity, defined by the Dis-
ease Activity Score in 28 joints using C-reactive protein level (DAS28-CRP) <2.6, the Simplified Disease Activity Index (SDAI)
£3.3, or the Clinical Disease Activity Index (CDAI)£2.8, and other health outcomes in a longitudinal observational study.
Methods. Other defined thresholds included low disease activity (LDA), moderate (MDA), or severe disease activity
(SDA). To control for intraclass correlation and estimate effects of independent variables on outcomes of the modified
Health Assessment Questionnaire (M-HAQ), the EuroQol 5-domain (EQ-5D; a quality-of-life measure), hospitalization,
and durable medical equipment (DME) use, we employed mixed models for continuous outcomes and generalized esti-
mating equations for binary outcomes.
Results. Among 1,297 subjects, achievement (versus nonachievement) of recommended disease targets was associated
with enhanced physical functioning and lower health resource utilization. After controlling for baseline covariates,
achievement of disease targets (versus LDA) was associated with significantly enhanced physical functioning based on
SDAI £3.3 (DM-HAQ 20.047; P5 0.0100) and CDAI £2.8 (20.073; P50.0003) but not DAS28-CRP <2.6 (20.022;
P5 0.1735). Target attainment was associated with significantly improved EQ-5D (0.022–0.096; P < 0.0030 versus LDA,
MDA, or SDA). Patients achieving guideline-recommended disease targets were 36–45% less likely to be hospitalized
(P < 0.0500) and 23–45% less likely to utilize DME (P < 0.0100).
Conclusion. Attaining recommended target disease-activity measures was associated with enhanced physical function-
ing and health-related quality of life. Some health outcomes were similar in subjects attaining guideline targets versus
LDA. Achieving LDA is a worthy clinical objective in some patients.
INTRODUCTION
Rheumatoid arthritis (RA) affects 0.5–1.0% of adults in
industrialized societies (1). This chronic, systemic inflam-
matory disorder causes erosive damage to articular cartilage
and subchondral bone, with joint swelling, deformity,
pain, stiffness, and fatigue. Many patients with RA experi-
ence diminished health-related quality of life (HRQOL) as
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well as increased disability and comorbidities. Because of
related disability, reduced worker productivity, expensive
therapy with biologic drugs, institutionalization, joint
replacement surgery, and increased use of durable medical
equipment (DME), RA is a costly condition, accounting for
annual health care expenditures of approximately $128 bil-
lion in the US (2–4).
Although there is no cure for RA, treatment with disease-
modifying antirheumatic drugs (DMARDs) and biologic
DMARDs (bioDMARDs) has improved health outcomes for
RA patients. Increasingly, treatments oriented toward pre-
specified disease targets are emerging as the prevailing RA
management paradigm. This treat-to-target approach
involves aiming for a prespecified target of disease activity,
frequently monitoring disease levels, and titrating medica-
tion regimens to goals (where therapies are acceptably tol-
erated). Such strategies have proved to be more effective
than routine care, with randomized controlled trials (RCTs)
and other studies supporting their value in attenuating RA
signs and symptoms, ameliorating functional status, and
mitigating or halting radiographic progression (5–8).
The most desirable target measure of disease activity is
remission, which signifies a condition of negligible or no
inflammatory activity, total arrest of structural joint dam-
age, and the optimum achievable reversal of disability
(6,9–11). In previous consensus guidelines, remission was
operationally defined as a Disease Activity Score in 28
joints using C-reactive protein level (DAS28-CRP) of ,2.6
(12). However, some patients with DAS28-CRP ,2.6 expe-
rience residual disease activity, including inflammation,
pain, and joint tenderness and swelling in ankle and foot
joints (5,13–18). Although DAS28-CRP ,2.6 no longer con-
stitutes remission, it remains a valid treatment target.
In more recent times, more stringent consensus defini-
tions of remission have been developed that are both index
based (Simplified Disease Activity Index [SDAI] score
#3.3 [3,13,19]) and Boolean based. The Boolean-based def-
inition (13) requires a score of #1 on each of the following
items: tender joint count in 28 joints, swollen joint count
in 28 joints, CRP level (in mg/dl), and patient global assess-
ment (on a 0–10-cm visual analog scale [13,19]).
Clinical studies have increasingly included different target
measures of disease activity as primary efficacy end points
(20–23). Because such trials typically include “selected”
patient populations with high adherence, severe RA activity,
and short study durations, their findings may be less general-
izable to clinical practice compared with data from observa-
tional studies (7,24–29).
Limited empirical evidence is available concerning
patients with established RA in routine clinical practice to
support the benefits of achieving different definitions of
target measures of disease activity in relation to functional
status, HRQOL, and health care resource utilization. To
our knowledge, no observational study has assessed the
potential clinical implications of achieving each of these
different disease cut points across various efficacy and
resource use outcome measures.
To close this gap in knowledge, we sought to evaluate
associations between achieving different definitions of tar-
get measures of disease activity and the following health
outcomes in a longitudinal observational study of a clini-
cally representative RA patient cohort: 1) physical func-
tioning (daily activities) according to the modified Health
Assessment Questionnaire (M-HAQ), 2) HRQOL according
to the EuroQol 5-domain (EQ-5D) measure, and 3) health
care resource utilization according to hospitalizations and
DME use.
PATIENTS AND METHODS
We utilized data from the Brigham and Women’s Hospital
Rheumatoid Arthritis Sequential Study (BRASS; Clinical-
Trials.gov identifier NCT01793103), which was initiated in
2003–2004. Details concerning the study design have been
reported elsewhere ([30–32]; for further details, see http://
www.brassstudy.org.). The BRASS Registry is a single-center,
prospective, observational longitudinal cohort of .1,200
adults with established or recent-onset RA who are being fol-
lowed by a hospital-based practice of 21 rheumatologists in
Boston. Physicians assessed patient demographic and clinical
characteristics, disease activity, and laboratory parameters at
baseline and annually thereafter. Followup postal question-
naires to assess patient-reported outcomes were also mailed
to patients every 6 months. In the BRASS Registry, disease
activity was evaluated during each annual rheumatology
visit. However, because visits seldom occurred exactly at
Significance & Innovations
 Data are limited on the benefits of achieving
guideline-recommended targets, as well as other
measures of disease activity, on the outcomes of
physical functioning, quality of life, and health
care resource utilization in established rheumatoid
arthritis (RA) within “real-world” clinical practice
settings.
 Our study evaluated associations between achieve-
ment of guideline targets, low disease activity
(LDA), moderate disease activity (MDA), or severe
disease activity (SDA) and physical functioning,
quality of life, and health care resource utilization.
 In our observational study of a mainly established RA
population, patients who achieved (versus did not
achieve) targets had improved physical functioning
and quality of life, as well as lower health care
resource utilization. However, benefits of attaining
target versus LDA were not uniform across all defini-
tions of disease activity; for example, patients achiev-
ing Simplified Disease Activity Index and Clinical
Disease Activity Index (but not Disease Activity
Score in 28 joints using C-reactive protein level) tar-
gets had significantly better physical functioning.
 We observed that, with each increasing (worsening)
measure of disease activity (i.e., LDA, MDA, SDA),
subjects experienced decreased physical function-
ing and health-related quality of life, as well as
increased resource use. Hence, LDA may also be a
clinically worthwhile alternative in patients who
do not achieve remission.
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12 months, for this analysis windows of 6 months (63
months) around the 12-month physician visits were created
to evaluate annual disease activity. In addition, windows of 3
months (61.5 months) were created around the 6-month
patient survey. Therefore, the followup time was divided into
distinct intervals as follows: time interval 1 extended from 5
to 8 months (midpoint56 months); interval 2 extended from
9 to 15 months (midpoint512 months); interval 3 extended
from 16 to 20 months (midpoint5 18 months); interval 4
extended from 21 to 27 months (midpoint524 months), and
so on, extending up to 5 years.
Measures of disease activity assessed annually by physi-
cians included the DAS28-CRP, the SDAI, and the Clinical
Disease Activity Index (CDAI). Three different desired target
measures of disease activity were considered in the current
analysis: DAS28-CRP ,2.6, SDAI #3.3, and CDAI #2.8
(33–35). These disease targets were categorized as having
been met or not met as follows: DAS28-CRP ,2.6 versus
$2.6, SDAI#3.3 versus.3.3, and CDAI#2.8 versus.2.8.
In addition to categorizing and comparing disease activity
in a binary manner, we compared achievement of the target
measures to attainment of multiple other cut points. Achieve-
ment of DAS28-CRP,2.6 was compared to attainment of low
disease activity (LDA; 2.6,DAS28-CRP#3.2), moderate dis-
ease activity (MDA; 3.2,DAS28-CRP # 5.1), or severe dis-
ease activity (SDA; DAS28-CRP .5.1) (33,35). Similarly,
achievement of SDAI #3.3 was compared to attainment of
LDA (3.3,SDAI #11.0), MDA (11.0,SDAI #26), or SDA
(SDAI .26) (36,37). Finally, achievement of CDAI#2.8 was
compared to attainment of LDA (2.8,CDAI #10.0), MDA
(10.0,CDAI#22.0), or SDA (CDAI.22.0) (34).
The patient-reported outcomes of physical functioning as
measured by the M-HAQ, HRQOL as measured by the EQ-
5D using US population-based preference weights (36), and
health care resource utilization as measured by whether
patients did (or did not) use DME or were (or were not) hos-
pitalized, were captured during the 6-month postal survey.
The patient-reported outcome measures incorporated with-
in the BRASS case report forms were validated question-
naires that have been widely used in other RA registries as
well as clinical trial settings (33–35,37). DME included
walkers, wheelchairs, standers, and patient lifts.
Ethics. The BRASS Registry has been conducted in accor-
dance with International Society for Pharmacoepidemiology
Guidelines for Good Pharmacoepidemiology Practices, appli-
cable regulatory requirements, and ethical tenets originating
in the Declaration of Helsinki. The study protocol and
informed consent document were reviewed and approved by
the Brigham and Women’s Hospital Institutional Review
Board. All patients provided written informed consent before
participating in the BRASS Registry. Anonymous (de-identi-
fied) patient data in the present study were compliant with
the Health Insurance Portability and Accountability Act.
Maintenance of patient confidentiality was assured by
assigning each subject a randomized identification number
upon enrollment in the BRASS Registry.
Statistical analyses. Baseline characteristics were ex-
pressed as means6SDs and numbers (%). Univariate and
multivariate analyses were conducted to evaluate associa-
tions between achievement of prespecified, guideline-
recommended target measures of disease activity (inde-
pendent variables of interest) and the outcome measures of
M-HAQ (continuous variable), EQ-5D (continuous vari-
able), DME use (categorical variable), and all-cause hospi-
talization (categorical variable; dependent variables).
Univariate analyses involved comparisons of mean scores
on the M-HAQ and EQ-5D, in patients who either did or did
not achieve the above definitions of targets for the DAS28-
CRP, SDAI, and CDAI, using Student’s t-test and analysis of
variance for comparing these measures in individuals attain-
ing target, LDA, MDA, or SDA. Similarly, proportions of
patients using DME or being hospitalized were compared in
patients who either did or did not achieve the above defini-
tions of targets, using the chi-square test and visual inspec-
tion comparisons between individuals attaining guideline-
recommended targets, LDA, MDA, or SDA.
To control for intraclass correlation of the panel data in
BRASS, we used mixed models with Toeplitz covariance
structure to estimate both the effects of the achievement of tar-
get measures or other levels of disease activity on the depen-
dent variables, i.e., the primary outcome measure of physical
functioning assessed by the M-HAQ and the secondary out-
come measure of HRQOL assessed by the EQ-5D. Generalized
estimating equations with binomial distribution and logit
link function were utilized for binary outcomes such as DME
use and all-cause hospitalization. Baseline covariates includ-
ed in these models were sociodemographic, laboratory meas-
ures, subjective (patient-reported), and physician-diagnosed
comorbidities (Supplementary Table 1, available on theArth-
ritis Care & Research web site at http://onlinelibrary.wiley.
com/doi/10.1002/acr.22678/abstract). A purposeful selection
method was used for identifying variables to be considered
for the multivariate models; that is, we included in the multi-
variate model only variables that had some association with
the outcome variable (i.e., had a P value of# 0.10, which was
the prespecified threshold). The selection of the final model
was based on evaluation of overall model fit statistics and
included an iterative model selection (backward as well as
stepwise) process and examination of variables that were
associated with outcomes.
Analyses were conducted using SAS PROC MIXED and
PROC GENMOD procedures for continuous and categori-
cal outcome variables.
RESULTS
Baseline characteristics of the 1,297 included subjects
(n 51,067 women [82.3%]) are summarized in Table 1. The
mean6SD age was 56.66 14.1 years, and the mean6SD
symptom duration was 15.36 13.0 years. Most patients
(70.7%) were seropositive and/or had received DMARDs
(86.7%), with some patients receiving bioDMARDs (n5 477,
36.8% of entire population) at baseline. In addition, some
patients had DAS28-CRP ,2.6 (n5 389, 30.0%), SDAI #3.3
(n591, 7.0%), or CDAI#2.8 (n5 134, 10.3%) at baseline.
Primary outcomemeasure: physical functioning (M-HAQ).
Subjects who achieved target measures of disease acti-
vity (i.e., DAS28-CRP ,2.6, SDAI #3.3, and CDAI #2.8)
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experienced improved physical functioning on the M-HAQ
compared to subjects who did not attain these target meas-
ures (Figure 1). In addition, BRASS registrants with incre-
mentally worse disease activity levels (i.e., LDA, MDA, and
SDA) experienced decreased physical functioning on the M-
HAQ compared to patients attaining the foregoing target
measures (Figure 2). After controlling for baseline covariates
in the mixed models, we found that achievement of DAS28-
CRP ,2.6 was associated with a mean reduction (improve-
ment) of 0.0823 in M-HAQ scores (P , 0.0001) compared to
not achieving DAS28-CRP ,2.6. Similarly, achieving (ver-
sus not achieving) SDAI #3.3 or CDAI ,2.8 was associated
with reductions in M-HAQ scores of 0.0834 (P , 0.0001)
and 0.1035 (P, 0.0001), respectively (Table 2).
Compared to individuals with LDA, subjects who
achieved these target measures of disease activity had
mean reductions (improvements) on M-HAQ scores of
0.0221 (P50.1735), 0.0471 (P5 0.0100), and 0.0734
(P5 0.0003) based on DAS28-CRP, SDAI, and CDAI crite-
ria, respectively. When compared to individuals with
MDA, subjects achieving these same target measures of
disease activity experienced mean reductions on M-HAQ
scores of 0.0875 (P , 0.0001), 0.0909 (P , 0.0001), and
0.1192 (P , 0.0001) based on DAS28-CRP, SDAI, and
CDAI criteria, respectively. Similar findings on physical
functioning were observed in BRASS registrants achieving
the target measures of disease activity compared to SDA
(Table 2): significant improvements in M-HAQ across
DAS28-CRP, SDAI, and CDAI categories (P , 0.0001 for
each comparison).
Other covariates significantly associated with improved
M-HAQ scores across all 3 composite measures included
prior treatment with methotrexate (MTX), lower baseline M-
HAQ score (i.e., less physical dysfunction at baseline),
shorter RA duration, an absence of osteoporosis, and being a
former (versus current) smoker (Supplementary Table 2,
available on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.22678/abstract).
Secondary outcome measures: HRQOL (EQ-5D) and
health care resource use. Similar findings to the M-HAQ
were evident concerning HRQOL on the EQ-5D and health
care resource use (DME and hospitalizations). Subjects who
achieved guideline-recommended target measures of disease
activity experienced enhanced HRQOL and decreased re-
source use, compared to those who did not attain these targets,
during each year of followup (Figure 1). (Numbers of patients
who achieved [or did not achieve] targets at each time point
are tabulated in Supplementary Table 3, available on theArth-
ritis Care & Research web site at http://onlinelibrary.wiley.
com/doi/10.1002/acr.22678/abstract).
Conversely, with each increasing (worsening) measure of
disease activity (i.e., LDA, MDA, and SDA), subjects experi-
enced decreased HRQOL and increased resource use com-
pared to their counterparts who achieved the target measures
(Figure 2). After controlling for baseline covariates in mixed
models, we found that subjects who achieved (versus did not
achieve) the foregoing target measures of disease activity
experienced significant improvements on the EQ-5D across
all 3 composite indices, with increases of 0.0478 to 0.0735 (P
, 0.0001 for each) (Table 2). Subjects who achieved the tar-
get measures of disease activity for DAS28-CRP, SDAI, and
CDAI experienced significantly improved HRQOL compared
to individuals with LDA, MDA, or SDA (each P, 0.0030).
Subjects who attained guideline-recommended target
measures of disease activity also had significantly (or bor-
derline significantly) lower odds of DME use and hospital-
ization (Table 3). The odds of DME use in subjects who
achieved (versus did not achieve) the targets was reduced
by approximately 23–45% for DAS28-CRP ,2.6 (odds
ratio [OR] 0.77, P50.0086), SDAI #3.3 (OR 0.61,
P50.0011), and CDAI #2.8 (OR 0.55, P5 0.0002). Reduc-
tions in the odds of DME use were also observed when
subjects achieving target measures were compared to
those with LDA on the SDAI and CDAI, with decreases of
36–39%. Across all 3 disease measures, subjects who
achieved the desired targets had significantly reduced
odds of DME use compared to individuals with SDA
(reductions of 40–55%; P , 0.0090 for each comparison)
(Table 3).
Findings on the odds of hospitalization were similar to
the data on DME use (Table 3). The odds of hospitalization
were significantly decreased, by approximately 36–45%,
among subjects who achieved (versus did not achieve) the
target measures of disease activity. Similar, significant
reductions in the odds of hospitalization were also
observed when comparing subjects who achieved the
desired targets to their counterparts with MDA or SDA
(but not LDA) across all measures.




Age, years (n5 1,297) 56.66 14.1
Symptom duration, years (n5 1,286) 15.36 13.0
Body mass index, kg/m2 (n51,227) 26.86 5.7
Diastolic blood pressure, mm Hg
(n5 1,157)
75.8610
DAS28-CRP (n5 1,255) 3.86 1.6
Swollen joints, total (n5 1,295) 6.96 7.2
Painful joints, total (n51,295) 7.76 7.9
Total swollen and painful joints
(n5 1,295)
14.76 14.2
Female sex (n51,297) 1,067 (82.3)
Anti-CCP positive (n51,117) 703 (62.9)
RF positive (n51,092) 693 (63.5)
Seropositive (n5 1,128) 797 (70.7)
M-HAQ (n51,220) 0.436 0.46
RA disease target measures
(n51,297)
DAS ,2.6 389 (30.0)
CDAI #2.8 134 (10.3)
SDAI #3.3 91 (7.0)
DMARD at baseline (n5 1,297) 1,124 (86.7)
Biologic DMARD at baseline
(n5 1,297)
477 (36.8)
* DAS28-CRP5Disease Activity Score in 28 joints using the
C-reactive protein level; anti-CCP5 anti–cyclic citrullinated protein;
RF5 rheumatoid factor; M-HAQ5modified Health Assessment
Questionnaire; RA5 rheumatoid arthritis; CDAI5Clinical Disease
Activity Index; SDAI5Simplified Disease Activity Index;
DMARD5disease-modifying antirheumatic drug.
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As with the M-HAQ data, baseline covariates signifi-
cantly associated with improved HRQOL on the EQ-5D
included lower M-HAQ scores (i.e., less physical dysfunc-
tion) and shorter RA duration across all 3 disease mea-
sures (Supplementary Table 4, available on the Arthritis
Care & Research web site at http://onlinelibrary.wiley.
com/doi/10.1002/acr.22678/abstract). A history of MTX
therapy was also associated with a significant improve-
ment in EQ-5D (increase of 0.018; P # 0.0021) for DAS28-
CRP ,2.6 but was not uniformly significantly associated
with improvements in EQ-5D according to SDAI or CDAI
disease targets (P. 0.07 for each).
DISCUSSION
This longitudinal observational cohort study demonstrat-
ed that achieving (versus not achieving) guideline-
recommended target measures of disease activity of
DAS28-CRP ,2.6, SDAI #3.3, and/or CDAI #2.8 was
associated with significant improvements in physical
functioning, HRQOL, and health care resource utilization.
Our findings are consistent with consensus guidelines,
which have been evolving toward a strategy of treating RA
to targets. Recently, a European League Against Rheuma-
tism panel stated that LDA “defined by composite mea-
sures is a good alternative goal for. . .patients who cannot
attain remission even today, especially those with long-
standing disease who. . .constitute the majority of patients
in clinical care” (5).
In this context, subjects who achieved the most desirable
target of DAS28-CRP, 2.6 in our study did not differ signif-
icantly compared to those with LDA (2.6#DAS28-CRP
,3.2) in terms of physical functioning as measured by the
M-HAQ. Attainment of DAS28-CRP ,2.6, SDAI #3.3, or
CDAI#2.8 did not result in significant reductions in hospi-
talization compared to achievement of LDA (although there
were trends toward reduced odds of hospitalization in sub-
jects achieving target measures across all 3 indices) but did
differ in HRQOL and DME use (significant or borderline sig-
nificant differences between DAS28-CRP ,2.6, SDAI #3.3,
or CDAI #2.8 versus LDA, MDA, or SDA). Our findings
therefore suggest that differentiation on outcome measures
for achieving target measures versus LDA is not uniform.
We also observed that attainment of LDA (versus MDA or
SDA) was associated with favorable clinical and economic
outcomes.
Most of the differences in outcomes observed between
groups were both statistically significant and clinically rele-
vant, in that they met minimum important differences
(MIDs). Even though there is no consensus concerning the
MID for M-HAQ in clinical practice settings, a 20.09 change
Figure 1. Mean modified Health Assessment Questionnaire (MHAQ) disability scores, EuroQol 5-domain (EQ-5D) health-related quality
of life scores, and durable medical equipment (DME) use among patients achieving targets (light bars) compared to those not achieving
target measures (dark bars). Disease targets were Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP)
,2.6, Simplified Disease Activity Index (SDAI) #3.3, or Clinical Disease Activity Index (CDAI) #2.8. For numbers of patients who
achieved (or did not achieve) the target at each time point, see Supplementary Table 3, available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22678/abstract.
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in the HAQ disability index has been associated with
“somewhat improved” outcomes (38). Assuming that a
change of20.09 is the MID for M-HAQ, most of the compari-
sons in Table 2 either approach or exceed this threshold,
except for comparisons between achieving guideline-
recommended disease targets and LDA, where only the
CDAI-based comparisons approached this difference.
To our knowledge, no investigators have reported a MID
for the EQ-5D in RA. However, work done in other disease
states indicates that the MID is a change of 0.05–0.08 on
Figure 2. Mean modified Health Assessment Questionnaire (MHAQ) disability scores, EuroQol 5-domain (EQ-5D) health-related quality
of life scores, and durable medical equipment (DME) use among patients with Disease Activity Score in 28 joints using the C-reactive
protein level (DAS28-CRP) ,2.6, Simplified Disease Activity Index (SDAI) #3.3, or Clinical Disease Activity Index (CDAI) #2.8 (light
bars) compared to low disease activity (dark bars), moderate disease activity (black bars), and severe disease activity (striped bars). Low
disease activity5 2.6,DAS28-CRP #3.2; 3.3,SDAI #11.0; 2.8,CDAI #10.0. Moderate disease activity53.2,DAS28-CRP #5.1;
11.0,SDAI #26; 10.0,CDAI #22.0. Severe disease activity5DAS28-CRP .5.1; SDAI .26.0; CDAI .22.0.
Table 2. Improvements in physical functioning (M-HAQ) and quality of life (EQ-5D) based on achieving target measures of







Mean difference in M-HAQ based on. . .
Achieving target (vs. not achieving) 20.0823 , 0.0001 20.0834 , 0.0001 20.1035 , 0.0001
Achieving target (vs. achieving LDA) 20.0221 0.1735 20.0471 0.0100 20.0734 0.0003
Achieving target (vs. achieving MDA) 20.0875 , 0.0001 20.0909 , 0.0001 20.1192 , 0.0001
Achieving target (vs. achieving SDA) 20.2040 , 0.0001 20.1476 , 0.0001 20.1611 , 0.0001
Mean difference in EQ-5D based on. . .
Achieving target (vs. not achieving) 0.0478 , 0.0001 0.0658 , 0.0001 0.0735 , 0.0001
Achieving target (vs. achieving LDA) 0.02247 0.0026 0.05180 , 0.0001 0.06117 , 0.0001
Achieving target (vs. achieving MDA) 0.05143 , 0.0001 0.06656 , 0.0001 0.08014 , 0.0001
Achieving target (vs. achieving SDA) 0.08492 , 0.0001 0.09145 , 0.0001 0.09602 , 0.0001
* Targets: Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) ,2.6, Simplified Disease Activity Index (SDAI) #3.3,
or Clinical Disease Activity Index (CDAI) #2.8. Low disease activity (LDA): 2.6,DAS28-CRP #3.2; 3.3,SDAI #11.0; 2.8,CDAI #10. Moderate
disease activity (MDA): 3.2,DAS28-CRP #5.1; 11,SDAI #26; 10,CDAI #22. Severe disease activity (SDA): DAS28-CRP .5.1; SDAI .26.0;
CDAI .22. M-HAQ5modified Health Assessment Questionnaire; EQ-5D5EuroQol 5-domain.
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the EQ-5D (39). Based on a MID of 0.05, all comparisons in
our analysis evaluating attainment of target versus LDA,
MDA, and SDA (based on CDAI and SDAI) crossed the
MID. On the other hand, consistent with the M-HAQ-
based analyses, DAS28-CRP-based comparisons crossed or
approached the MID, with the exception of attaining target
compared to LDA. Taken together, these findings support
both the value of treating to targets and the assertion that
LDA is a plausible alternative clinical objective for treat-
to-target strategies when guideline-recommended goals
cannot be achieved in clinical practice.
In our study, previous treatment with MTX was associat-
ed with significantly enhanced physical functioning on the
M-HAQ, while duration of RA, baseline M-HAQ, current
(versus former) smoking, and osteoporosis (versus absence
of osteoporosis) were associated with significantly worse
physical functioning. These findings extend data from a
Swedish case–control study, which determined that smok-
ing was dose dependently associated with occurrence of
anti–cyclic citrullinated peptide (anti-CCP) antibodies (40).
An interaction between HLA–DR shared epitope genes and
smoking triggered immune responses only in patients posi-
tive for anti-CCP. In this context, most of our patients (63%)
were anti-CCP positive at baseline. Finally, a study of
patients with LDA or MDA revealed a significant associa-
tion between radiographic damage in RA and low femoral-
neck bone mineral density (41).
All outcome measures did not perform consistently in dis-
criminating dependent variables of physical functioning,
HRQOL, and health care resource utilization across
guideline-recommended target measures and levels of dis-
ease activity in our study. Previous reports indicated that
data from all 3 indices are overall highly intercorrelated and
show similarly high C-statistics (area under the curve values
.0.80) for receiver operating characteristic curves when
using, as “gold standards,” clinicians’ decisions either to ini-
tiate DMARDs or to increase their doses. The SDAI and
CDAI include both patient and evaluator ratings of global
disease activity, which are frequently discrepant (36). Per-
haps the inclusion of both perspectives on global disease
activity in the SDAI and CDAI (but not DAS28-CRP) renders
these indices more effective assessments of physical func-
tioning on the M-HAQ (versus DAS28-CRP).
Data concerning improvements in patient-reported and
resource use outcomes based on achievement of specific lev-
els of disease activity in patients with established or chronic
RA are limited. Most studies were conducted in subjects
with recent-onset RA (26–28,42,43). Unlike many RCTs
involving individuals with recent-onset RA, the BRASS Reg-
istry was an observational cohort study that included sub-
jects with a mean age of 56.6 years and a mean RA duration
of 15.3 years. At baseline, the mean DAS28-CRP was 3.8
(consistent with moderate RA), fewer than 11% of subjects
were in CDAI or SDAI remission, approximately 87%
received conventional DMARDs, and 37% received bio-
DMARDs. Given these characteristics, we consider our find-
ings to be generalizable to most established RA populations
typically encountered in clinical practices.
To our knowledge, this is the only study that formally
evaluated associations between achievement of guideline-
recommended targets and the likelihood of using durable
equipment, such as canes, walkers, and wheelchairs. Utili-
zation of DME was significantly (or borderline significantly)
reduced in subjects with DAS28-CRP ,2.6, SDAI #3.3, or
CDAI #2.8 (versus LDA, MDA, or SDA on each of these
measures). BRASS registrants who achieved (versus did not
achieve) guideline disease targets were at significantly (up
to 45%) reduced odds of DME use and hospitalization. The
magnitudes of these benefits were stronger with SDAI and
CDAI compared to DAS28-CRP for DME use.
In a somewhat similar, but smaller (n5356), study of
patients with established RA, Radner et al recently demon-
strated significant benefits associated with achieving a
guideline-recommended disease target (versus LDA) in sub-
jects with a baseline mean age of 59.9 years and a mean dis-
ease duration of 11.5 years (6). This trial assessed changes
in dependent variables, including physical functioning,
HRQOL (by EQ-5D and Short Form 36 health survey), work-
er productivity, overall activity impairment, and health
care costs, as functions of the independent variable of







ORs for DME use based on. . .
Achieving target (vs. not achieving) 0.77 0.64–0.94 0.61 0.46–0.82 0.55 0.40–0.75
Achieving target (vs. achieving LDA) 0.79 0.60–1.00 0.64 0.46–0.88 0.61 0.43–0.86
Achieving target (vs. achieving MDA) 0.84 0.67–1.00 0.70 0.50–0.96 0.55 0.39–0.77
Achieving target (vs. achieving SDA) 0.60 0.45–0.80 0.51 0.37–0.70 0.45 0.32–0.63
ORs for all-cause hospitalization based on. . .
Achieving target (vs. not achieving) 0.64 0.51–0.80 0.61 0.46–0.82 0.55 0.40–0.75
Achieving target (vs. achieving LDA) 0.73 0.51–1.05 0.73 0.44–1.21 0.66 0.40–1.10
Achieving target (vs. achieving MDA) 0.72 0.54–0.95 0.55 0.33–0.91 0.55 0.33–0.92
Achieving target (vs. achieving SDA) 0.38 0.27–0.52 0.39 0.24–0.64 0.44 0.27–0.27
* Targets: Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) ,2.6, Simplified Disease Activity Index (SDAI) #3.3,
or Clinical Disease Activity Index (CDAI) #2.8. Low disease activity (LDA): 2.6,DAS28-CRP #3.2; 3.3,SDAI #11.0; 2.8,CDAI#10. Moderate
disease activity (MDA): 3.2,DAS28-CRP #5.1; 11,SDAI #26; 10,CDAI #22. Severe disease activity (SDA): DAS28-CRP . 5.1; SDAI .26.0;
CDAI .22. 95% CI5 95% confidence interval; ORs5odds ratios; DME5durable medical equipment.
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achieving SDAI #3.3 (versus LDA or moderate to severe
disease activity [SDAI .11]) but not the other disease tar-
gets evaluated in our study (i.e., DAS28-CRP and CDAI).
Unlike our investigation, the study by Radner et al pooled
data for patients with MDA and SDA because there were
small numbers of patients with SDA. Patients achieving
SDAI #3.3 in the investigation by Radner and colleagues
had significantly better physical functioning, work produc-
tivity, and superior HRQOL compared to those achieving
LDA. When explaining their findings, the authors suggested
that the long RA duration may have resulted in an overall
very disabled cohort. In this same European study, subjects
with more severe levels of disease had higher total direct
costs, as well as costs for both sick leave and disability (6).
These findings were extended by the Dutch Rheumatoid
Arthritis Monitoring (DREAM) study, which demonstrated
a larger gain in quality-adjusted life years with a treat-to-
target (versus usual care) clinical approach and an incre-
mental cost-effectiveness ratio of e3,591 per subject in
remission after 2 years with the treat-to-target strategy (7).
The observational nature of our study permitted enroll-
ment of a large number of subjects who were followed over
prolonged intervals (up to 5 years). In theory, our findings
may have been influenced by selection bias, in that patients
who responded to postal surveys and/or visited clinics to
measure disease activity might have differed from nonres-
pondents. DME use and hospitalization were self-reported,
opening the possibility of recall bias or nonrandom missing
values. Nonrandom patient attrition could also have intro-
duced biases. A previous study of the BRASS Registry iden-
tified disease duration, disease activity, and differences in
drug therapy to be associated with attrition. However, dur-
ing the years included in the current analysis, patient fol-
lowup in the BRASS Registry was highly acceptable (32).
Of approximately 1,300 patients enrolled in the BRASS
Registry, 83% had followup data at year 1, 78% at year 2,
73% at year 3, 77% at year 4, and 76% at year 5. Hence, we
believe that the impact of patient attrition on the findings of
our analysis was small.
Findings from observational studies are typically more
generalizable to usual care settings compared with RCTs. On
the other hand, observational analyses are of an inherently
associational nature and cannot conclusively assign causality
or rule out certain biases, even though we controlled for all
relevant baseline covariates. Longitudinal studies such as
ours are also potentially subject to limitations related to miss-
ing data. Outcome measures within a single individual over
time are also intercorrelated. To handle these issues, mixed
models such as those employed in our study represent poten-
tially advantageous approaches because all available data are
included, irrespective of whether subjects had unequal num-
bers of observations or unequal time intervals between them.
Finally, we did not evaluate associations between achieve-
ment of different disease cut points and other patient-
reported outcomes, such as pain, depression, anxiety, or
fatigue, as well as objective measures such as radiographic
progression.
In conclusion, this longitudinal observational study of a
typical RA cohort (BRASS Registry) demonstrated benefits of
treat-to-target strategies, with clinical objectives of DAS28-
CRP,2.6, SDAI#3.3, and CDAI#2.8, in enhancing physical
function and HRQOL, as well as reducing DME use and hos-
pitalization. Evidence also supported the value of treat-to-
target strategies with an objective of low (versus moderate or
severe) disease activity. Our findings are compatible with the
use of guideline-recommended target measures of disease
activity as treatment objectives in clinical practice as well as
LDA in patients who cannot attain guideline-recommended
targets. Additional studies are needed to evaluate associa-
tions between achievement of different target measures of
disease activity and other patient-reported (e.g., pain, fatigue)
and radiographic (e.g., total Sharp score) outcomes, as well as
actual costs rather than the odds of DME use and hospitaliza-
tion, in other typical clinical settings.
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